20-F/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F/A

(Amendment 1)

[  ] REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

[X]	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended December 31, 2020

OR

[  ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from ___________ to ___________

OR

[  ]	SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	Date of event requiring this shell company report

Commission file number: 333-207107

EHAVE, INC

(Exact name of Registrant as specified in its charter)

Canada

(Jurisdiction of incorporation or organization)

18851 NE 29^th Ave., Suite 700

Aventura, FL 33180

(Address of principal executive offices)

Securities registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Securities registered pursuant to Section 12(g) of the Act.

Common Shares, no par value

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 67,169,962 common shares as at December 31, 2020

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [  ] No [X]

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes [  ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [  ]	Accelerated filer [  ]	Non-accelerated filer [X]
		Emerging growth company [X]

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. [X]

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. [  ]

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

US GAAP	International Financial Reporting Standards as issued by the International Accounting Standards Board	Other
[X]	[  ]	[  ]

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:

Item 17 [  ]             Item 18 [  ]

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

EXPLANATORY NOTE 

The purpose of this Amendment No. 1 (this “Amendment”) to our Annual Report on Form 20-F for the period ended December 31, 2020 (the “Form 20-F”), as filed with the Securities and Exchange Commission (the “SEC”) on May 28, 2021, is solely to furnish Exhibit 101 to the Form 20-F in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 20-F formatted in XBRL (eXtensible Business Reporting Language).

ITEM 19. EXHIBITS.

The following exhibits are filed as part of this annual report:

Exhibit Number	Description
1.1	Articles of Incorporation (1)
1.2	Articles of Amendment to the Articles of Incorporation dated November 30, 2011 (2)
1.3	Articles of Amendment to the Articles of Incorporation dated May 13, 2015 (3)
1.4	Articles of Amendment to the Articles of Incorporation dated June 26, 2015 (4)
1.5	Articles of Amendment to the Articles of Incorporation dated November 4, 2015 (5)
1.6	Articles of Amendment to the Articles of Incorporation dated May 28, 2019 (5A)
1.7	Bylaws No. 2 (6)
4.6	License Agreement, dated April 24, 2015, between the Company and The Governing Counsel of the University of Toronto (12)
4.13	Master Services Agreement, dated December 8, 2015 with Blog Inc LLC (dba Cress & Company) (19)
4.20	Note and Warrant Purchase Agreement, dated as of November 14, 2016 (26)
4.21	Form of Convertible Promissory Note (27)
4.22	Strategic Relationship Agreement, dated as of February 3, 2017, between the Company and MedReleaf Corp. (28)
4.23	Amendment to API Integration & Distribution Agreement, dated as of May 4, 2017, between the Company and MHS (29)
4.34	Agreement, dated March 1, 2018, between the Company and Revive Therapeutics Ltd. (40)
4.35	Agreement, dated March 5, 2018, between the Company and Aequus Pharmaceuticals Inc. (41)
4.36	Services Agreement, dated January 15, 2017, between the Company and NView Management Inc. (42)
4.37	Services Agreement, dated April 23, 2018, between the Company and Dianne Parsons, C.P.A. (43)
4.39	Form of Note Conversion Agreement (Premium, 2018 Notes)(45)
4.40	Form of Note Conversion Agreement (Regular, 2016 Notes)(46)
4.41	Form of Note Conversion Agreement (Regular, 2018 Notes)(47)
4.42	Form of Promissory Note dated September 27, 2018 (48)
4.43	Form of Promissory Note dated September 27, 2018 (49)
4.44	Agreement, dated October 30, 2018, between the Company and Companion Healthcare Technologies. (50)
4.45	Form of Promissory Note dated November 29, 2018 (51)
4.46	Form of Promissory Note dated October 31, 2018 (52)
4.47	Loan Agreement dated January 1, 2019 (53)
4.48	Form of Promissory Note dated January 28, 2019 (54)
4.49	Form of Promissory Note dated January 28, 2019 (55)
4.50	Form of Warrant Cancellation (56)
4.51	Memorandum of Understanding, dated February 27, 2019, between the Company and David Goyette, Chief Technology Officer (57)
4.52	Memorandum of Understanding, dated February 27, 2019, between the Company and Prateek Dwivedi, Chief Executive Officer (58)
4.53	Form of Bridge Loan Agreement (59)
4.54	Form of Bridge Loan Note (60)
4.55	Agreement, dated February 27, 2019, between the Company and Bezalel Partners LLC (61)
4.56	Agreement, dated February 27, 2019, between the Company and KW Capital Partners Ltd (62)
4.57	Agreement, dated February 27, 2019, between the Company and Scott Woodrow (63)
4.58	Form of Note Conversion - Bridge Loan Note (64)
4.59	Form of Promissory Note dated March 26, 2019 (65)
4.60	Asset Purchase Agreement, dated March 22, 2019, between Ehave, Inc. and ZYUS Life Sciences Inc. (66)
4.61	Form of Security Agreement, to be entered into between Ehave, Inc. and ZYUS Life Sciences Inc. (67)
4.62	Form of Non-Competition Agreement, to be entered into between Ehave, Inc. and ZYUS Life Sciences Inc. (68)
4.63	Minutes of Settlement, dated April 18, 2019, between Ehave, Inc. and Companion Healthcare Technologies (69)
4.64	Executive Consulting Agreement dated June 24, 2019 between the Company and Ben Kaplan (70)
4.65	2020 Ehave Equity Incentive Plan (71)
12.1*	Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12.2*	Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
13.1*	Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
13.2*	Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance File
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Presentation Linkbase Document

*Filed herewith

(1)	Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(2)	Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(3)	Incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(4)	Incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(5)	Incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(5A)	Incorporated by reference to Exhibit 3.1 to the Company’s Report on Form 6-k filed with the SEC on May 24, 2019
(6)	Incorporated by reference to Exhibit 3.5 to the Form 6-K filed with the SEC on January 12, 2017.
(12)	Incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form F-1/A filed with the SEC on November 16, 2015.
(19)	Incorporated by reference to Exhibit 10.27 to the Company’s Registration Statement on Form F-1/A filed with the SEC on March 11, 2016.
(26)	Incorporated by reference to Exhibit 99.1 to the Form 6-K filed with the SEC on November 23, 2016.
(27)	Incorporated by reference to Exhibit 99.2 to the Form 6-K filed with the SEC on November 23, 2016.
(28)	Incorporated by reference to Exhibit 4.22 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(29)	Incorporated by reference to Exhibit 4.23 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(40)	Incorporated by reference to Exhibit 4.34 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(41)	Incorporated by reference to Exhibit 4.35 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(42)	Incorporated by reference to Exhibit 4.36 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(43)	Incorporated by reference to Exhibit 4.37 to the Company’s Annual Report on Form 20-F filed with the SEC on August 16, 2018.
(44)	Incorporated by reference to Exhibit 4.38 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(45)	Incorporated by reference to Exhibit 4.39 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(46)	Incorporated by reference to Exhibit 4.40 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(47)	Incorporated by reference to Exhibit 4.41 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(48)	Incorporated by reference to Exhibit 4.42 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(49)	Incorporated by reference to Exhibit 4.43 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(50)	Incorporated by reference to Exhibit 4.44 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(51)	Incorporated by reference to Exhibit 4.45 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(52)	Incorporated by reference to Exhibit 4.46 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(53)	Incorporated by reference to Exhibit 4.47 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(54)	Incorporated by reference to Exhibit 4.48 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(55)	Incorporated by reference to Exhibit 4.49 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(56)	Incorporated by reference to Exhibit 4.50 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(57)	Incorporated by reference to Exhibit 4.51 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(58)	Incorporated by reference to Exhibit 4.52 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(59)	Incorporated by reference to Exhibit 4.53 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(60)	Incorporated by reference to Exhibit 4.54 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(61)	Incorporated by reference to Exhibit 4.55 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(62)	Incorporated by reference to Exhibit 4.56 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(63)	Incorporated by reference to Exhibit 4.57 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(64)	Incorporated by reference to Exhibit 4.58 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(65)	Incorporated by reference to Exhibit 4.59 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(66)	Incorporated by reference to Exhibit 4.60 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(67)	Incorporated by reference to Exhibit 4.61 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(68)	Incorporated by reference to Exhibit 4.62 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(69)	Incorporated by reference to Exhibit 4.63 to the Company’s Annual Report on Form 20-F filed with the SEC on June 14, 2019.
(70)	Incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 6-K filed with the SEC on July 22, 2019
(71)	Incorporated by reference to Exhibit 4.1 to the Company’s Report on Form 6-K filed with the SEC on August 20, 2020.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

Date: May 28, 2021

EHAVE, INC.

/s/ Ben Kaplan

Ben Kaplan

Chief Executive Officer

/s/ Jay Cardwell

Jay Cardwell

Chief Financial Officer

EX-12.1

Exhibit 12.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT

I, Benjamin Kaplan, certify that:

1.	I have reviewed this annual report on Form 20-F/A of Ehave, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4.	The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: May 28, 2021

/s/ Benjamin Kaplan

Benjamin Kaplan

Chief Executive Officer and Chairman

EX-12.2

Exhibit 12.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT

I, Jay Cardwell, certify that:

1.	I have reviewed this annual report on Form 20-F/A of Ehave, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
4.	The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.	Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.	Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5. The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: May 28, 2021

/s/ Jay Cardwell

Jay Cardwell

Chief Financial Officer

EX-13.1

Exhibit 13.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Ehave, Inc. (the “Company”) hereby certifies, to such officer’s knowledge that:

1.	The accompanying Annual Report on Form 20-F/A of the Company for the year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 28, 2021

/s/ Benjamin Kaplan

Benjamin Kaplan

Chief Executive Officer and Chairman

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-13.2

Exhibit 13.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Ehave, Inc. (the “Company”) hereby certifies, to such officer’s knowledge that:

1.	The accompanying Annual Report on Form 20-F/A of the Company for the year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 28, 2021

/s/ Jay Cardwell

Jay Cardwell

Chief Financial Officer

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

XML

Document and Entity Information	12 Months Ended
	Dec. 31, 2020 shares
Cover [Abstract]
Entity Registrant Name	Ehave, Inc.
Entity Central Index Key	0001653606
Document Type	20-F/A
Document Period End Date	Dec. 31, 2020
Amendment Flag	true
Amendment Description	The purpose of this Amendment No. 1 (this "Amendment") to our Annual Report on Form 20-F for the period ended December 31, 2020 (the "Form 20-F"), as filed with the Securities and Exchange Commission (the "SEC") on May 28, 2021, is solely to furnish Exhibit 101 to the Form 20-F in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 20-F formatted in XBRL (eXtensible Business Reporting Language).
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity's Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	67,169,962
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false

XML

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 1,865,110	$ 17,530
Prepaid expenses	24,247	7,804
Refundable taxes		30,831
Investments	26,250
Other current assets	40,000
Total current assets	1,955,607	56,165
Other receivables		440,572
TOTAL ASSETS	1,955,607	496,737
CURRENT LIABILITIES:
Accounts payable	382,225	521,432
Taxes payables	6,613	6,541
Other payables	2,751,326	281,527
Advances from former officers and directors	30,736	30,400
Promissory notes	349,079	270,018
Current portion of convertible notes, net of debt discount of $200,313	222,493	142,352
Derivative liability		1,250,584
Accrued interest on promissory notes and convertible notes	53,929	51,075
Total current liabilities	3,796,401	2,553,929
Long-term portion of convertible notes, net of debt discount of $1,310,921	432,578
Development grant		173,583
TOTAL LIABILITIES	4,228,979	2,727,512
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT:
Common stock, no par value, unlimited shares authorized, 67,169,962 and 25,413,920 issued and outstanding as of December 31, 2020 and 2019, respectively	7,948,416	7,503,984
Additional paid in capital	9,379,990	6,338,430
Accumulated deficit	(19,729,562)	(16,214,826)
Accumulated other comprehensive income	127,784	141,637
TOTAL STOCKHOLDERS' DEFICIT	(2,273,372)	(2,230,775)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,955,607	$ 496,737

XML

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Debt discount current	$ 200,313	$ 200,313
Debt discount non current	$ 1,310,921
Common stock, no par value
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	67,169,962	25,413,920
Common stock, shares outstanding	67,169,962	25,413,920

XML

Consolidated Statements of Operations and Other Comprehensive Income - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses
General and administrative	$ 2,046,573	$ 411,019
Total operating expenses	2,046,573	411,019
OPERATING LOSS	(2,046,573)	(411,019)
Other income (expenses)
Interest expense	(2,016,324)	(172,334)
Amortization expense	(804,356)
Change in fair value of derivative liability	(3,004,387)
Change in fair value of warrant liability
Gain on settlement of debt	4,179,971
Other income	176,933
Foreign exchange (gain) loss		(1,099)
Net income (loss) from continuing operations	(3,514,736)	(584,452)
Loss from discontinued operations		(3,701,024)
Gain on sale of intangible assets, net		648,108
Net loss from discontinued operations		(3,052,916)
Net income (loss)	(3,514,736)	(3,637,368)
Other comprehensive (loss) income
Foreign exchange translation adjustment	(13,853)	(157,541)
Total other comprehensive income	(13,853)	(157,541)
Comprehensive income (loss)	(3,528,589)	(3,794,909)
AMOUNTS ATTRIBUTABLE TO COMMON STOCKHOLDERS
Loss from continuing operations	(3,528,589)	(741,993)
Loss from discontinued operations		(3,052,916)
COMPREHENSIVE NET LOSS	$ (3,528,589)	$ (3,794,909)
Basic	$ (0.11)	$ (0.03)
Diluted	(0.11)	(0.03)
Basic		(0.14)
Diluted		(0.14)
NET INCOME (LOSS) PER SHARE:
Basic	(0.11)	(0.18)
Diluted	$ (0.11)	$ (0.18)
WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic	32,622,248	21,454,189
Diluted	32,622,248	21,454,189

XML

Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated (Deficit) [Member]	Accumulated Other Comprehensive Income [Member]	Total
Beginning balance at Dec. 31, 2018	$ 1,544,904	$ 6,999,942	$ (12,577,458)	$ 299,178	$ (3,733,434)
Beginning balance, shares at Dec. 31, 2018	751,108
Stock based compensation	$ 2,131,920	19,871			2,151,791
Stock based compensation, shares	4,263,840
Stock issued in exchange for vested options	$ 681,383	(681,383)
Stock issued in exchange for vested options, shares	48,399
Share issuance upon Exchange Agreement	$ 3,145,777				$ 3,145,777
Share issuance upon Exchange Agreement, shares	20,350,573
Foreign exchange translation				(157,541)	(157,541)
Net Income Loss			(3,637,368)		(3,637,368)
Ending balance at Dec. 31, 2019	$ 7,503,984	6,338,430	(16,214,826)	141,637	(2,230,775)
Ending balance, shares at Dec. 31, 2019	25,413,920
Stock based compensation		928,795			928,795
Stock based compensation, shares	2,433,357
Fair value of warrants issued in connection with convertible debt		1,412,539			1,412,539
Fair value of beneficial conversion feature issued in connection with convertible debt		700,226			700,226
Common stock issued upon conversion of debt	$ 378,182				378,182
Common stock issued upon conversion of debt, shares	37,818,154
Common stock issued for CureDash	$ 40,000				40,000
Common stock issued for CureDash, shares	353,622
Common stock issued for Psytech	$ 26,250				26,250
Common stock issued for Psytech,shares	1,050,000
Common stock issued upon cashless warrant exercise
Common stock issued upon cashless warrant exercise, shares	100,909
Foreign exchange translation				(13,853)	(13,853)
Net Income Loss			(3,514,736)		(3,514,736)
Ending balance at Dec. 31, 2020	$ 7,948,416	$ 9,379,990	$ (19,729,562)	$ 127,784	$ (2,273,372)
Ending balance, shares at Dec. 31, 2020	67,169,962

XML

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (3,514,736)	$ (3,637,368)
Loss from discontinued operations		3,052,916
Loss from continuing operations	(3,514,736)	(584,452)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	928,795
Amortization of debt discount	896,348
Non-cash interest expense	1,874,963
Gain on settlement of debt	(4,179,971)
Gain on forgiveness of development grant	(176,933)
Change in fair value of derivative liability	3,004,387
Change in fair value of warrant liability
Changes in operating assets and liabilities:
Other receivables	438,579	(1,314)
Prepaid expenses and other assets	(16,729)	(7,804)
Accounts payable and other payables	677,531	(80,062)
Accrued interest on convertible notes	45	111,994
Refundable taxes receivable	29,701	(21,077)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES - CONTINUING OPERATIONS	(38,021)	(582,715)
NET CASH USED IN OPERATING ACTIVITIES - DISCONTINUED OPERATIONS		(298,649)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	(38,021)	(881,363)
NET CASH PROVIDED BY INVESTING ACTIVITIES:
NET CASH PROVIDED BY INVESTING ACTIVITIES - CONTINUING OPERATIONS		648,108
NET CASH PROVIDED BY INVESTING ACTIVITIES - DISCONTINUED OPERATIONS
NET CASH PROVIDED BY INVESTING ACTIVITIES		648,108
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes	2,238,170	545,018
Repayment of convertible notes	(141,000)
Financing fees	(63,500)
Repayment of promissory notes	(138,561)	(275,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES - CONTINUING OPERATIONS	1,895,109	270,018
NET CASH PROVIDED BY FINANCING ACTIVITIES -DISCONTINUED OPERATIONS
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,895,109	270,018
Effect of exchange rate on cash	(9,508)	(30,455)
Net increase in cash	1,847,580	6,308
Cash, beginning of period	17,530	11,222
Cash, end of period	1,865,110	17,530
SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for conversion of debt	378,182
Common stock issued for CureDash	40,000
Common stock issued for Psytech	26,250
Accrued interest converted to common stock		300,362
Debt converted to common stock		$ 2,845,414

XML

Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. ORGANZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and General Description of Business

EHAVE, Inc. (formerly known as “Behavioural Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011. The Company is a publicly listed company whose shares are quoted on the Pink Open Market under the symbol EHVVF in the United States. On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market because we were unable able to cure our bid price deficiency.

The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our clinically validated digital assessment and rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

The COVID-19 outbreak, which surfaced in Wuhan, China in December 2019 and which was subsequently declared a pandemic by the World Health Organization in March 2020, has had a pronounced effect on the domestic and global economies. The Company’s business has been materially adversely impacted by the recent COVID-19 outbreak and may continue to be materially adversely impacted in the future. The extent of the impact of COVID-19 on the Company’s business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning the severity and action taken to contain or prevent further spread within the U.S. and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted.

Basis of Presentation and principles of consolidation

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its wholly owned subsidiary, Mycotopia Therapies, Inc. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation.

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as the Company does not have more than $1,070,000,000 in annual gross revenue and did not have such amount as of December 31, 2020, its last fiscal year. The Company has elected to take advantage of the extended transition period provided in Section 102(b)(1) of the JOBS Act for complying with new or revised accounting standards.

Foreign Currency Translation

The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.

Foreign Currency Risk

The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are primarily in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.

Software Products and Research and Development

Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method.

Income Taxes

Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

The Company has made applications for Ontario Interactive Digital Media Tax Credits (“OIDMTC”). Judgment is required in the determination of qualifying expenses. The final determination of qualifying expenses is not known until acceptance by tax authorities. The Company’s credits have been reflected in the financial statements. (See Note. 5 “Other Receivable”)

Net Loss per Common Share, basic

The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. At December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.

Recent Pronouncements

During the years ended December 31, 2020 and 2019 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

XML

Going Concern

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

2. GOING CONCERN

The accompanying financial statements have been prepared in conformity with generally accepted accounting principles in the United States, which contemplate the continuation of the Company as a going concern.

Through December 31, 2020, the Company has incurred an accumulated deficit of $19,729,562, primarily as a result of expenses incurred through a combination of development and commercialization activities related to our products and general and administrative expenses supporting those activities, as well as an operating loss of $3,514,736. Our total cash balance as of December 31, 2020 was $1,865,110. At December 31, 2020, we had a working capital deficit of $1,840,794. We anticipate that we will continue to incur losses and negative cash flows from operations, and that such losses will increase over the next several years. As a result of these expected losses and negative cash flows from operations, along with our current cash position, we may not have sufficient resources to fund operations for one year from the date we issued these financial statements. Therefore, there is substantial doubt about our ability to continue as a going concern.

XML

Fair Value Measurement

12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurement

3. FAIR VALUE MEASUREMENT

ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Refundable taxes, accounts payable, development grant and convertible notes are all stated at book value due to the term and nature of such items.

XML

Sale of Intangible Assets and Discontinued Operation

12 Months Ended

Dec. 31, 2020

Sale Of Intangible Assets And Discontinued Operation

Sale of Intangible Assets and Discontinued Operation

4. SALE OF INTANGIBLE ASSETS AND DISCONTINUED OPERATION

On March 22, 2019 the Company entered into an asset purchase agreement with Zyus Life Sciences, Inc. (“Zyus”) and completed the sales of certain intellectual property assets and rights relating to the Company’s health informatics platform (the “Asset Purchase Agreement”). In accordance with the Asset Purchase Agreement, the Company received in the aggregate from Zyus (i) CAD $1.2 million in cash, and (ii) 361,011 of Zyus common shares. During the year ended December 31, 2019, the Company recorded CAD $551,892 of expenses directly associated with the Asset Purchase Agreement and recorded a gain on the sale of intangible assets, net, in the amount of $648,108. There is no value recorded for the Zyus common shares due to the lack of an active market and ascertainable value.

With the consummation of this sale, the Company’s current operations were discontinued due to the elimination of the ongoing operations and cash flows of the component, the resignation of then current executive management and abandonment of its leased facilities.

Operating results for the years ended December 31, 2019 for the Ehave Connect platform and related operating expenses are presented as discontinued operations as follows:

	Year Ended December 31,
	2019
Operating expenses from discontinued operation
General and administrative expenses	$	2,450,440
Total operating expenses from discontinued operation		2,450,440
OPERATING LOSS FROM DISCONTINUED OPERATION		(2,450,440	)
Change in fair market value of derivative liabilities		(1,250,584	)
Gain on sale of intangible assets, net		648,108
Net loss from discontinued operations	$	(3,052,916	)

XML

Other Receivable

12 Months Ended

Dec. 31, 2020

Other Receivable

Other Receivable

5. OTHER RECEIVABLE

As of December 31, 2019, other receivables includes $300,018 that relates to filed applications for Ontario Interactive Media Tax Credits. The Company recently filed an amended 2016 tax return and its 2018 tax return in order to receive payment for the Ontario Interactive Media Tax Credits. The review process has been completed and the Canada Revenue Agency issued the refund in full.

XML

Related Party Transactions

12 Months Ended

Dec. 31, 2020

Related Party Transactions [Abstract]

Related Party Transactions

6. RELATED PARTY TRANSACTIONS

The related party transactions are as follows:

During the year ended December 31, 2020, the Company issued two convertible promissory notes to a related party for the principal amount of $256,520, in the aggregate, including $23,320 of original issue discount and 2,565,200 warrants, in the aggregate, with an exercise price of $0.01 per share. The term of the notes is 18 months and carries an effective interest rate of 8.00%. $178,189 of the note matures on July 17, 2021 and $78,331 matures on July 29, 2021. The convertible promissory note is convertible into shares of common stock at $0.01 per share.

During the year ended December 31, 2020, the Company issued a convertible promissory note to a related party for the principal amount of $11,000, in the aggregate, including $1,000 of original issue discount and 110,000 warrants, in the aggregate, with an exercise price of $0.01 per share. The term of the note is 18 months and carries an effective interest rate of 8.00%. The note matures on May 11, 2022.

On August 4, 2020, the Company issued 775,194 shares of common stock, in the aggregate, to two individuals who are a related party and directors of the Company for services rendered.

On April 18, 2019, the Company terminated the agreement it entered into CHT on October 30, 2018 (the “CHT Agreement”) regarding the exclusive rights to Ehave Connect granted to CHT for use in companion animals. Pursuant to the agreement to terminate the CHT Agreement, the Company paid CHT, in cash, CAD $230,170, which includes CAD $25,170 for legal fees that CHT incurred in connection with the CHT Agreement, from the proceeds of the Asset Sale.

On January 28, 2019, the Company issued demand non-interest bearing senior secured promissory notes in the aggregate principal amount of $85,756 (CAD$125,000), including $18,841(CAD$25,000) of original issue discount. Binyomin Posen and Zeke Kaplan, directors of the Company, have personal and business relations with some of the lenders. The principal amount of $85,756 was repaid on May 24, 2019.

On February 27, 2019, the Company issued 1,268,378 common shares of the Company valued at $634,189 in exchange for services performed by multiple parties, one of which is a significant shareholder. Binyomin Posen and Zeke Kaplan, directors of the Company, have personal and business relations with one of the vendors who exchanged fees.

On February 27, 2019, we entered into an exchange agreement (the “Exchange Agreement”) with a significant shareholder to convert the 2018 unsecured debentures, secured debentures, and senior secured promissory notes (the “2018 Converted Debt”) into common stock. Under the terms of the Exchange Agreement, the Company issued in the aggregate 20,350,573 shares of common stock upon the conversion of, in the aggregate, $3,145,777 of outstanding principal and interest and the cancellation of 560,461 warrants related to the 2018 Converted Debt.

On September 24, 2018, the Company entered into a letter agreement (the “Letter Agreement”) in which the Company and Scott Woodrow, a related party and former Director of the Company, agreed to convert the outstanding convertible debentures and cancel the outstanding warrants. On February 27, 2019, the Company granted 475,642 shares of common stock to Scott Woodrow in connection with the letter agreements.

On March 26, 2019, the Company issued demand non-interest bearing senior secured promissory notes in the aggregate principal amount of $98,351 (CAD$131,683), including $23,663 (CAD$31,683) of original issue discount. Binyomin Posen and Zeke Kaplan, directors of the Company, have personal and business relations with some of the lenders. The principal amount of $95,351 was repaid on May 24, 2019.

On June 24, 2019, the Company entered into an Executive Consulting Agreement with Benjamin Kaplan to serve as the Company’s CEO for an initial term of 24 months. As of December 31, 2020 and 2019, the Company has accrued $2,194,963 and $172,091, respectively, as other payables in relation to the Executive Consulting Agreement. Of the $2,194,963, $1,874,963 was recorded as interest expense during the year ending December 31, 2020 related to 15,624,694 shares of common stock owed in relation to capital raises. During the year ending December 31, 2020, the Company has recorded $1,040,694 as general and administrative expense related to compensation of which $720,964 is recorded as stock based compensation. During the year ending December 31, 2019, the Company recorded $172,091 as general and administrative expense related to the Executive Consulting Agreement.

XML

Promissory and Convertible Notes

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Promissory and Convertible Notes

7. PROMISSORY AND CONVERTIBLE NOTES

During the year ended December 31, 2020, the Company issued convertible promissory notes in the principal amount of $2,544,487, in the aggregate, and including $267,520 issued to related parties. The principal amount includes $231,317 of original issue discount and 2,544,870 warrants with an exercise price of $0.01 per share. The term of the notes are 18 months and carry an effective interest rate of 8.00%. The notes mature beginning on July 10, 2021 thru June 28, 2022. The convertible promissory notes are convertible into shares of common stock at $0.01 per share. The Company recorded a debt discount in the amount of $2,407,582, in the aggregate, in relation to the original issue discount, conversion feature and warrants. During the year ended December 31, 2020, the Company converted $378,182 of principal debt and issued 37,818,154 shares of common stock, in the aggregate, upon conversion of the convertible promissory notes. During the year ended December 31, 2020, the Company recorded amortization expense in the amount of $896,348 in relation to the amortization of debt discount of which $804,356 was recorded as amortization expense in relation to the warrants and conversion feature and $91,992 was recorded as interest expense in relation to the original issue discount and financing fees in the consolidated statements of operations and comprehensive income.

On January 21, 2019, we issued a senior secured promissory note in the aggregate principal amount of $263,192 (CAD$350,000). The secured promissory note is secured against certain of our assets, including all development tax credits that the Company has applied for and receives. During the year ending December 31, 2020, the Company repaid the note in full.

On January 28, 2019, we issued demand non-interest bearing senior secured promissory notes in the aggregate principal amount of $85,756 (CAD$125,000), including $18,841(CAD$25,000) of original issue discount. The principal amount of $85,756 was repaid on May 24, 2019.

Exchange Agreement

On February 27, 2019, we entered into Exchange Agreement with a significant shareholder to convert the 2018 Converted Debt into common stock. Under the terms of the Exchange Agreement, the Company issued in the aggregate 20,350,573 shares of common stock upon the conversion of, in the aggregate, $3,145,777 of outstanding principal and interest and the cancellation of 560,461 warrants related to the 2018 Converted Debt (see Note 6).

XML

Development Grant

12 Months Ended

Dec. 31, 2020

Development Grant

Development Grant

8. DEVELOPMENT GRANT

On June 7, 2012, the Company entered into a project funding agreement with the Canada-Israel Research and Development Foundation (“CIIRDF”). The purpose of the grant was to fund the Company’s activities related to the development of a cognitive assessment and treatment platform for childhood attention deficit disorder and attention hyperactivity disorder (the “Development”). Under the terms of the grant, CIIRDF would fund up to CAD$300,000 of development activities related to the Development. The grant is repayable to CIIRDF based on 2.5% of annual gross sales related to products developed from the Development. The Company received CAD$225,000 from CIIRDF to fund the Development. The Company no longer pursues the Development, and the grant is no longer payable as no sales will be generated from the Development. During the year ending December 31, 2020, the Company recorded $176,933 as other income in relation to the grant.

XML

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

9. INCOME TAXES

The Company computes income taxes using the asset and liability approach. The Company currently has no issue that creates timing differences that would mandate a deferred tax expense. Due to the uncertainty as to the utilization of net operating loss carryforwards, a valuation allowance has been made to the extent of any tax benefit that net operating losses may generate. No provision for income tax has been recorded for the years ended December 31, 2020 and December 31, 2019 due to the Company’s operating losses.

The Company previously filed applications for Ontario Interactive Digital Media Tax Credits (the “Tax Credits”). During the year ending December 31, 2020, the Company was refunded the Tax Credits in full. As of December 31, 2020 and 2019, the Company has a net operating loss for tax purposes of CAD $8,603,671 and CAD $6,143,402, respectively, that can be carried forward over 20 years.

Deferred Income Taxes

Deferred income taxes primarily represent the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts for income tax purposes. The components of the Company’s deferred taxes are as follows:

	2020			2019
Deferred tax assets (liabilities):
Deferred tax asset, beginning	$	741,000		$	704,000
Increase in valuation reserve		333,000			37,000
Deferred tax asset, ending		1,074,000			741,000
Valuation Allowance		(1,074,000	)		(741,000	)
Net Deferred tax assets	$	-		$	-

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. COMMITMENTS AND CONTINGENCIES

Collaboration Agreement

The Company entered into a collaboration agreement with a hospital located in Canada. As of December 31, 2020 and 2019, a the Company recorded $10,000 and $5,000, respectively, for the annual royalty due under the terms of the collaboration agreement.

Consulting Agreement

On June 24, 2019, the Company entered into an Executive Consulting Agreement (Agreement) with Benjamin Kaplan (BK) to serve as the Company’s CEO for an initial term of 24 months. In addition to the monthly consulting fee, the Agreement provides for a one month ‘termination fee’ if the Agreement is terminated without cause.

On June 29, 2019, the Company and BK amended the Agreement as follows:

BK was granted a Warrant to purchase that number of shares of common stock of the Company equal to 5% of the issued and outstanding common shares, on a fully diluted basis. The Warrant was issued on April 16, 2020, has an exercise price of $0.01 USD per share and shall expire April 16, 2022.

Upon the closing of a Significant Transaction (defined as the closing of financing for at least $500,000 or the closing of an acquisition with a valuation (determined by the value of the consideration paid by the Company) of not less than $1,000,000 USD), BK would be granted a number of shares equal to 5% of the issued and outstanding common shares, on a fully diluted basis including such shares to be issued or that could be issued pursuant to the transaction on the closing date of such Significant Transaction. This stock grant can be earned by BK for each Significant Transaction closed during the term of the Agreement. As of December 31, 2020, a Significant Transaction has not consummated. During the year ending December 31, 2020, the Company closed the significant transaction and raised over $500,000. As of December 31, 2020, the Company owes BK 15,624,694 shares of common stock. As of and for the year ended December 31, 2020, the Company recorded $1,874,963 as other payables and interest expense in relation to the shares owed.

On January 1, 2020, the Company entered into a consulting agreement for investor relations services. The Company shall pay the consultant $6,500 per month for services rendered to be paid $2,500 in cash and $4,000 in common shares of the Company to be valued at a 20% discount to the lowest trading price for the five trading days prior to date upon which payment is due. As of and during the year ending December 31, 2020, the Company recorded $109,159 as other payables and consulting expense related to this agreement. As of December 31, 2020, the Company owed 876,225 shares of common stock in relation to this agreement.

Medical Advisory Board Agreements

During the year ended December 31, 2020, the Company entered into medical advisory board agreements with three members for a term of one year each. As consideration for the services to be rendered, the Company agreed to pay $10,000 in cash and $155,000 worth of stock in common stock. During the year ended December 31, 2020, the Company recorded $105,438 as general and administrative expense in accordance with the agreements. As of December 31, 2020, the Company accrued $105,438 as other payables in accordance with these agreements.

Leases

The Company currently reimburses an entity owned by its CEO for office space and related expenses that he has under lease. The lease expense is $2,500 per month. The Company does not own or lease any other office space, manufacturing facilities or equipment and does not have any current plans to construct or acquire any facilities. During the years ending December 31, 2020 and 2019, the Company expensed approximately $73,000 and $18,000, respectively, for office space and related expenses. As of December 31, 2020 and 2019, the Company accrued approximately $91,000 and $18,000 as other payables for amounts owed to the entity.

Novel coronavirus

Any serious disruption with the Company’s suppliers or customers due to the COVID-19 outbreak could impair the Company’s ability to meet and/or generate demand for its product, which may negatively impact the Company’s revenue, financial condition, and commercial operations. Such outbreaks could also result in delays in or the suspension of the Company’s research and product development activities, regulatory work streams, its clinical studies and other important functions. The Company is unable to predict the outcome of these matters and is unable to make a meaningful estimate of the amount or range of loss, if any, that could result from an unfavorable outcome.

XML

Stockholders' Equity (Deficit)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Stockholders' Equity (Deficit)

11. STOCKHOLDERS’ EQUITY (DEFICIT)

On September 15, 2020, the Company issued 1,050,000 shares of common stock in accordance with a strategic alliance agreement and as consideration for the purchase of 1,050,000 share of Psychedelitech, Inc. (“Psychedelitech”) (a private Ontario corporation). As a result of the transaction, the Company purchased 10% of Psychedelitech. The shares were recorded at fair market value on the date of issuance of $26,250. As of December 31, 2020, the investment in Psychedelitech is recorded at cost in the amount of $26,250.

During the year ended December 31, 2020, the Company issued 37,818,154 shares of common stock, in the aggregate, upon conversion of the convertible promissory notes (see Note 7).

During the year ended December 31, 2020, the Company issued 100,909 shares of common stock upon the cashless exercise of 110,000 warrants.

On December 31, 2020, the Company issued 353,622 shares of common stock in relation to an asset sale and purchase agreement entered into on January 21, 2021 (see “Subsequent Events”). The shares were recorded at fair market value on the date of issuance of $40,000. As of December 31, 2020, the Company recorded this amount as other current asset in the consolidated balance sheet.

On February 27, 2019, the Company converted $2,845,414 (CAD $3,740,431), the net carrying value of the principal balance of convertible notes payable and promissory notes payable, and $300,362 (CAD $394,693) of accrued interest into 19,711,362 shares of common stock pursuant to letter agreements with the holders of existing notes and warrants.

STOCK BASED COMPENSATION

During the year ended December 31, 2020, the Company entered into a finder’s fee agreement with a consultant to assist the Company in procuring sources of financing such as equity, debt, or a merger or sale of the Company. Total compensation for the consultant’s efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent. During the year ending December 31, 2020, the Company issued 1,250,000 shares of common stock which was recorded at fair value of $46,875 and paid $63,500 in relation to the finder’s fee agreement. The Company recognized these amounts as interest expense in the Company’s consolidated statements of operations and other comprehensive loss during the year ended December 31, 2020.

During the year ended December 31, 2020, the Company issued 3,358,498 vested warrants to Ben Kaplan, the Company’s CEO, in accordance with his employment agreement valued at $720,695. The Company expensed $720,695 as general and administrative expense in relation to this issuance. The Company valued these warrants using the Black-Scholes option pricing model using the following assumptions: a) stock prices of $0.37 and $0.12, b) exercise price of $0.01, c) dividend rate of 0%, d) risk free rates of 0.20% and 0.13%, and e) expected volatility of 570% and 648%.

On August 1, 2020, the Company issued 408,163 shares of common stock to a consultant for services rendered. The Company expensed $61,224 in relation to this issuance.

On August 4, 2020, the Company issued 387,597 shares of common stock to a member of management for services rendered. The Company expensed $50,000 in relation to this issuance.

On August 4, 2020, the Company issued 387,597 shares of common stock to a related party for services rendered. The Company expensed $50,000 in relation to this issuance.

On February 27, 2019, the Company granted 475,642 shares of common stock to Scott Woodrow, a related party and former Director of the Company, in connection with letter agreements (see Note 6).

On February 27, 2019, the Company issued 317,095 shares of common stock in exchange for services fair valued at $158,547 to KW Capital Partners Ltd.

On February 27, 2019, the Company issued 475,642 shares of common stock in exchange for services fair valued at $237,821 to Bezalel Partners LLC.

On February 27, 2019, the Company entered into an agreement to cancel 2,250,000 compensation warrants that had anti-rachet and anti-dilution provisions for 328,111 common shares of the Company.

A Summary of the status of the Company’s option grants as of December 31, 2020 and 2019 and the changes during the periods then ended is presented below:

	Shares			Weighted- Average Exercise Price		Weighted Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value
Outstanding January 1, 2019		86,251		$	-		5.0	$	-
Granted		-			-		-		-
Exercised		-			-		-		-
Canceled		(86,251	)		-		-		-
Outstanding December 31, 2019		-			-		-		-
Granted		-			-		-		-
Exercised		-			-		-		-
Canceled		-			-		-		-
Outstanding December 31, 2020		-		$	-		-	$	-

Warrants Issued

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the year ended December 31, 2020 and 2019

	Underlying Shares			Weighted Average Exercise Price		Weighted Average Term (Years)
Warrants outstanding at January 1, 2019		561,461		$	-		-
Granted		-			-		-
Exercised		-			-		-
Forfeited		560,461			-		-
Warrants outstanding at December 31, 2019		-			-		-
Granted		28,803,368			0.01		1.41
Exercised		(110,000	)		0.01
Forfeited		-			-		-
Warrants outstanding and exercisable at December 31, 2020		28,693,368		$	0.01		1.12

The intrinsic value of warrants outstanding as of December 31, 2020 was $2,926,612.

The warrants granted during the year ending December 31, 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

	Year Ended December 31, 2020
Expected term, in years		2.83
Expected volatility		162.24	%
Risk-free interest rate		0.44	%
Dividend yield		-

XML

Subsequent Events

12 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

12. SUBSEQUENT EVENTS

Subsequent to December 31, 2020, the Company issued 15,649,446 shares of common stock upon the conversion of $156,494 of convertible notes payable.

On January 19, 2021, the Company consummated its agreement with the former and current directors of 20/20 Global, Inc. (“20/20 Global”) that provide for: (i) 20/20 Global’s purchase for $350,000 in cash of all of the outstanding stock of Mycotopioa Therapies, Inc. (“MYC”), the Company’s wholly owned subsidiary, from Ehave under a Stock Purchase Agreement, resulting in MYC becoming a wholly owned subsidiary of 20/20 Global; and (ii) the change of control of 20/20 Global’s board of directors and management. In a related transaction, Ehave agreed to purchase 9,793,754 shares of 20/20 Global common stock, which constitute approximately 75.77% of the issued and outstanding shares of 20/20 Global’s common stock, for $350,000 in cash.

On January 19, 2021, the above transaction closed. Because Ehave acquired 75.77% of 20/20 Global outstanding stock and there was a change in control of 20/20 Global’s board of directors, the transaction was accounted for as a reverse merger in which Mycotopia Therapies, Inc. was deemed to be the accounting acquirer and 20/20 Global the legal acquirer.

On January 21, 2021, the Company entered into an asset sale and purchase agreement with CureDash, Inc. (a Delaware Corporation) (“CureDash” or the “Seller”). The Company purchased tangible and intangible assets from the Seller in order to begin a new venture in psychosis therapy. The purchase price of the assets is $100,000 payable with the issuance of 353,622 shares of common stock and $60,000 in cash which was paid upon closing on January 21, 2021.

Subsequent to year end, the Company received aggregate investments of $1,159,000 and issued 16,557,142 shares of common stock from the Regulation A Offering that was qualified in January 2021.

Subsequent to year end, the Company received proceeds of $522,000 from promissory notes. The notes carry an additional original issue discount payable of $52,750 representing interest as no other interest accrues on the notes unless there is an event of default, at which time interest will accrue at 22.0%, The notes mature eighteen months after the dates of issuance. The holder of the notes can exercise conversion at any time the note remains outstanding at a price of $0.01 per share. Upon the closing of a financing event of the Company, the notes will automatically convert at the conversion price of $0.01 per share. Attached to the notes is a warrant to purchase common stock entitling the holder to purchase up to a number of shares equal to ten times the face amount of the note at an exercise price of $0.01 per share. The warrant expires two years from the date of issuance.

Subsequent to year end, the Company issued 1,746,084 shares of common stock upon the cashless exercise of 1,870,000 warrants.

Subsequent to year end, the Company issued 281,000 shares of common stock is accordance with a medical advisory board agreement.

XML

Organization and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Organization and General Description of Business

Organization and General Description of Business

EHAVE, Inc. (formerly known as “Behavioural Neurological Applications and Solutions or 2304101 Ontario Inc.”) (“We” or “the Company”), was incorporated under the laws of the Province of Ontario, Canada on October 31, 2011. The Company is a publicly listed company whose shares are quoted on the Pink Open Market under the symbol EHVVF in the United States. On April 30, 2019, our common shares were removed from the OTCQB Venture Market to the Pink Open Market because we were unable able to cure our bid price deficiency.

The Company is a healthcare company developing a health data platform that integrates with proprietary and third-party assessment and therapeutic digital applications. Our product focus is based on two tiers of activities: (1) MegaTeam and Ninja Reflex, our clinically validated digital assessment and rehabilitation software that is engaging for the patient, (2) adaptation of third-party clinically validated digital assessment and rehabilitation software for enhanced patient engagement and data modeling. We intend to provide technology solutions to clinicians, patients, researchers, pharmaceutical companies and payors.

The COVID-19 outbreak, which surfaced in Wuhan, China in December 2019 and which was subsequently declared a pandemic by the World Health Organization in March 2020, has had a pronounced effect on the domestic and global economies. The Company’s business has been materially adversely impacted by the recent COVID-19 outbreak and may continue to be materially adversely impacted in the future. The extent of the impact of COVID-19 on the Company’s business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning the severity and action taken to contain or prevent further spread within the U.S. and the related impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted.

Basis of Presentation and Principles of Consolidation

Basis of Presentation and principles of consolidation

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. The Company’s functional currency is Canadian dollars. The Company’s fiscal year-end is December 31. The consolidated financial statements include the amounts of the Company and its wholly owned subsidiary, Mycotopia Therapies, Inc. All inter-company accounts and transaction have been eliminated in consolidation. Certain reclassifications have been made to the prior period condensed consolidated financial statements to conform to the current period presentation.

The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as the Company does not have more than $1,070,000,000 in annual gross revenue and did not have such amount as of December 31, 2020, its last fiscal year. The Company has elected to take advantage of the extended transition period provided in Section 102(b)(1) of the JOBS Act for complying with new or revised accounting standards.

Foreign Currency Translation

Foreign Currency Translation

The functional currency of the Company’s foreign operations is generally the local currency of the country in which the operation is located. All assets and liabilities are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Revenue and expenses are translated using average exchange rates during the period. The result from currency translation is reflected in stockholders’ deficit as a component of accumulated other comprehensive income.

Foreign Currency Risk

Foreign Currency Risk

The Company is exposed to fluctuations in the exchange rate between the United States dollar and the Canadian dollar. The Company’s continued financing activities are primarily in United States dollars while the Company’s expenditures are primarily in Canadian dollars. Should the exchange rate between the Canadian dollar and the United States dollar fluctuate, the Company may be exposed to resource constraints.

Software Products and Research and Development

Software Products and Research and Development

Software development costs are expensed as incurred and consist primarily of design and development costs of new products, and significant enhancements to existing products incurred before the establishment of technological feasibility. Costs incurred subsequent to technological feasibility of new and enhanced products, costs incurred to purchase or to create and implement internal-use software, and software obtained through business acquisitions are capitalized. Such costs are amortized over the estimated useful lives of the related products, using the straight-line method.

Income Taxes

Income Taxes

Income tax expense is based on income before income taxes and is accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded when it is more likely than not that a deferred tax asset will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Considerable judgment is required in assessing and estimating these amounts and the difference between the actual outcome of these future tax consequences and the estimates made could have a material impact on the operating results. To the extent that new information becomes available which causes the Company to change its judgment regarding the adequacy of existing tax liabilities, such changes to tax liabilities will impact income tax expense in the period in which such determination is made. The Company records interest and penalties related to unrecognized tax benefits in income tax expense.

The Company has made applications for Ontario Interactive Digital Media Tax Credits (“OIDMTC”). Judgment is required in the determination of qualifying expenses. The final determination of qualifying expenses is not known until acceptance by tax authorities. The Company’s credits have been reflected in the financial statements. (See Note. 5 “Other Receivable”)

Net Loss Per Common Share, Basic

Net Loss per Common Share, basic

The Company has adopted Accounting Standards Codification (“ASC”) subtopic 260-10, Earnings Per Share (“ASC 260-10”) specifying the computation, presentation and disclosure requirements of earnings per share (EPS) information. Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings or losses of the entity. At December 31, 2020, the Company had outstanding warrants to purchase 28,693,368 common shares and 216,630,546 common shares issuable upon the conversion of debt excluded from weighted average diluted common shares because their inclusion would have been antidilutive.

Recent Pronouncements

Recent Pronouncements

During the years ended December 31, 2020 and 2019 there were several new accounting pronouncements issued by the Financial Accounting Standards Board (FASB). Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

XML

Sale of Intangible Assets and Discontinued Operation (Tables)

12 Months Ended

Dec. 31, 2020

Sale Of Intangible Assets And Discontinued Operation - Schedule Of Discontinued Operations Of Operating Expenses

Schedule of Discontinued Operations of Operating Expenses

Operating results for the years ended December 31, 2019 for the Ehave Connect platform and related operating expenses are presented as discontinued operations as follows:

	Year Ended December 31,
	2019
Operating expenses from discontinued operation
General and administrative expenses	$	2,450,440
Total operating expenses from discontinued operation		2,450,440
OPERATING LOSS FROM DISCONTINUED OPERATION		(2,450,440	)
Change in fair market value of derivative liabilities		(1,250,584	)
Gain on sale of intangible assets, net		648,108
Net loss from discontinued operations	$	(3,052,916	)

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Components of Deferred Tax Assets

The components of the Company’s deferred taxes are as follows:

	2020			2019
Deferred tax assets (liabilities):
Deferred tax asset, beginning	$	741,000		$	704,000
Increase in valuation reserve		333,000			37,000
Deferred tax asset, ending		1,074,000			741,000
Valuation Allowance		(1,074,000	)		(741,000	)
Net Deferred tax assets	$	-		$	-

XML

Stockholders' Equity (Deficit) (Tables)

12 Months Ended

Dec. 31, 2020

Equity [Abstract]

Schedule of Stock Option Activity

A Summary of the status of the Company’s option grants as of December 31, 2020 and 2019 and the changes during the periods then ended is presented below:

	Shares			Weighted- Average Exercise Price		Weighted Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value
Outstanding January 1, 2019		86,251		$	-		5.0	$	-
Granted		-			-		-		-
Exercised		-			-		-		-
Canceled		(86,251	)		-		-		-
Outstanding December 31, 2019		-			-		-		-
Granted		-			-		-		-
Exercised		-			-		-		-
Canceled		-			-		-		-
Outstanding December 31, 2020		-		$	-		-	$	-

Schedule of Warrants Activity

The following table reflects a summary of Common Stock warrants outstanding and warrant activity during the year ended December 31, 2020 and 2019

	Underlying Shares			Weighted Average Exercise Price		Weighted Average Term (Years)
Warrants outstanding at January 1, 2019		561,461		$	-		-
Granted		-			-		-
Exercised		-			-		-
Forfeited		560,461			-		-
Warrants outstanding at December 31, 2019		-			-		-
Granted		28,803,368			0.01		1.41
Exercised		(110,000	)		0.01
Forfeited		-			-		-
Warrants outstanding and exercisable at December 31, 2020		28,693,368		$	0.01		1.12

Schedule of Weighted Average Assumptions of Warrants

The warrants granted during the year ending December 31, 2020 were valued using the Black-Scholes option pricing model using the following weighted average assumptions:

	Year Ended December 31, 2020
Expected term, in years		2.83
Expected volatility		162.24	%
Risk-free interest rate		0.44	%
Dividend yield		-

XML

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)		12 Months Ended
	Feb. 27, 2019	Dec. 31, 2020
Antidilutive Securities excluded from computation of earnings per share, amount	328,111
Warrants [Member]
Antidilutive Securities excluded from computation of earnings per share, amount		28,693,368
Common Shares [Member]
Antidilutive Securities excluded from computation of earnings per share, amount		216,630,546
Minimum [Member]
Emerging growth company, expected minimum gross revenue		$ 1,070,000,000

XML

Going Concern (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (19,729,562)	$ (16,214,826)
Net loss	(3,514,736)	(3,637,368)
Cash	1,865,110	$ 17,530
Working capital deficit	$ 1,840,794

XML

Sale of Intangible Assets and Discontinued Operation (Details Narrative)		12 Months Ended
	Mar. 22, 2019 CAD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 CAD ($)
Gain on sale of intangible assets, net			$ 648,108
Asset Purchase Agreement [Member] | Zyus Life Sciences, Inc [Member]
Number of shares acquired on purchase of assets | shares	361,011
Asset Purchase Agreement [Member] | Zyus Life Sciences, Inc [Member] | CAD [Member]
Cash received from agreement	$ 1,200,000
Expenses related to purchase agreement				$ 551,892
Gain on sale of intangible assets, net			$ 648,108

XML

Sale of Intangible Assets and Discontinued Operation - Schedule of Discontinued Operations of Operating Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Sale Of Intangible Assets And Discontinued Operation - Schedule Of Discontinued Operations Of Operating Expenses
General and administrative expenses		$ 2,450,440
Total operating expenses from discontinued operation		2,450,440
OPERATING LOSS FROM DISCONTINUED OPERATION		(2,450,440)
Change in fair market value of derivative liabilities		(1,250,584)
Gain on sale of intangible assets, net		648,108
Net loss from discontinued operations		$ (3,052,916)

XML

Other Receivable (Details Narrative)	Dec. 31, 2019 USD ($)
Ontario Interactive Media Tax Credits [Member]
Other receivables	$ 300,018

XML

Related Party Transactions (Details Narrative)										12 Months Ended
	Aug. 04, 2020 shares	Aug. 02, 2020 shares	May 24, 2020 USD ($)	Apr. 18, 2020 CAD ($)	Jun. 24, 2019	May 24, 2019 USD ($)	Feb. 27, 2019 USD ($) shares	Feb. 27, 2019 USD ($) shares	Feb. 27, 2019 USD ($) shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	Jun. 29, 2019 $ / shares	Mar. 26, 2019 USD ($)	Mar. 26, 2019 CAD ($)	Jan. 28, 2019 USD ($)	Jan. 28, 2019 CAD ($)
Debt instrument, principal amount							$ 2,845,414	$ 2,845,414	$ 2,845,414
Number of shares issued for services, shares | shares	378,597	408,163
Debt conversion shares issued | shares							19,711,362
Cancellation of warrants | shares										100,909
General and administrative expenses										$ 2,046,573	$ 411,019
Stock based compensation										928,795
CAD [Member]
Debt instrument, principal amount							$ 3,740,431	$ 3,740,431	$ 3,740,431
CHT Agreement [Member] | CAD [Member] | Cash Payment [Member]
Repayments to related party debt				$ 230,170
CHT Agreement [Member] | CAD [Member] | Legal Fees in Connection with Agreement [Member]
Repayments to related party debt				$ 25,170
Executive Consulting Agreement [Member]
Repayments to related party debt										2,194,963	172,091
Interest expenses on debt										$ 1,874,963
Common stock owed | shares										15,624,694
General and administrative expenses										$ 1,040,694	$ 172,091
Executive Consulting Agreement [Member] | General and Administrative Expense [Member]
Stock based compensation										$ 720,964
Directors [Member]
Number of shares issued for services, shares | shares	775,194
Multiple Parties [Member]
Number of shares issued for services, shares | shares								634,189
Number of shares issued for services								$ 1,268,378
Scott Woodrow [Member] | Exchange Agreement [Member]
Debt conversion shares issued | shares									475,642
Benjamin Kaplan [Member]
Warrants exercise price | $ / shares										$ 0.01
Cancellation of warrants | shares										3,358,498
General and administrative expenses										$ 720,695
Benjamin Kaplan [Member] | Executive Consulting Agreement [Member]
Warrants exercise price | $ / shares												$ 0.01
Term of notes					24 months
Related Party [Member]
Number of shares issued for services, shares | shares	775,194
Two Convertible promissory Notes [Member]
Debt instrument, principal amount										256,520
Debt original issue discount										$ 23,320
Aggregate of warrants | shares										2,565,200
Warrants exercise price | $ / shares										$ 0.01
Term of notes										18 months
Debt instrument, interest rate										8.00%
Convertible Promissory Note One [Member]
Debt instrument, principal amount										$ 178,189
Debt instrument, maturity date										Jul. 17, 2021
Convertible Promissory Note Two [Member]
Debt instrument, principal amount										$ 78,331
Debt instrument, maturity date										Jul. 29, 2021
Convertible Promissory Note Three [Member]
Debt instrument, principal amount										$ 11,000
Debt original issue discount										$ 1,000
Aggregate of warrants | shares										110,000
Warrants exercise price | $ / shares										$ 0.01
Term of notes										18 months
Debt instrument, interest rate										8.00%
Debt instrument, maturity date										May 11, 2022
Debt instrument conversion price per share | $ / shares										$ 0.01
Demand Non-Interest Secured Promissory Notes [Member]
Debt instrument, principal amount															$ 85,756
Debt original issue discount															$ 18,841
Demand Non-Interest Secured Promissory Notes [Member] | CAD [Member]
Debt instrument, principal amount																$ 125,000
Debt original issue discount																$ 25,000
Demand Non-Interest Unsecured Promissory Note [Member]
Debt instrument, principal amount													$ 98,351
Debt original issue discount													23,663
Repayments to related party debt			$ 85,756
Demand Non-Interest Unsecured Promissory Note [Member] | Repayment of Debt [Member]
Repayments to related party debt						$ 95,351
Demand Non-Interest Unsecured Promissory Note [Member] | CAD [Member]
Debt instrument, principal amount														$ 131,683
Debt original issue discount													$ 31,683
2018 Converted Debt [Member] | Exchange Agreement [Member]
Debt instrument, principal amount							$ 3,145,777	$ 3,145,777	$ 3,145,777
Debt conversion shares issued | shares							20,350,573	20,350,573
Cancellation of warrants | shares							560,461	560,461	560,461

XML

Promissory and Convertible Notes (Details Narrative)				12 Months Ended
	May 24, 2019 USD ($)	Feb. 27, 2019 USD ($) shares	Feb. 27, 2019 USD ($) shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	Jan. 28, 2019 USD ($)	Jan. 21, 2019 USD ($)	Jan. 21, 2019 CAD ($)
Debt principal amount		$ 2,845,414	$ 2,845,414
Number of warrant issued | shares				100,909
Debt discount				$ 200,313	$ 200,313
Debt converted into shares | shares		19,711,362
Amortization expenses				804,356
Amortization of debt discount				896,348
Number of warrants cancelled | shares		2,250,000
CAD [Member]
Debt principal amount		$ 3,740,431	3,740,431
Convertible Promissory Note [Member]
Debt principal amount				2,544,487
Original issue discount				$ 231,317
Number of warrant issued | shares				2,544,870
Warrants exercise price | $ / shares				$ 0.01
Term of notes				18 months
Debt interest rate				8.00%
Debt maturity description				The notes mature beginning on July 10, 2021 thru June 28, 2022.
Debt instrument conversion price per share | $ / shares				$ 0.01
Debt discount				$ 2,407,582
Debt converted into shares, value				$ 378,182
Debt converted into shares | shares				37,818,154
Amortization expenses				$ 896,348
Amortization of debt discount				804,356
Interest expenses on debt				91,992
Convertible Promissory Note [Member] | Related Party [Member]
Debt principal amount				$ 267,520
Senior Secured Promissory Notes [Member]
Debt principal amount						$ 85,756	$ 263,192
Original issue discount						18,841
Repayments of debt	$ 85,756
Senior Secured Promissory Notes [Member] | CAD [Member]
Debt principal amount						125,000		$ 350,000
Original issue discount						$ 25,000
2018 Converted Debt [Member] | Exchange Agreement [Member]
Debt principal amount		$ 3,145,777	$ 3,145,777
Number of warrant issued | shares		560,461	560,461
Debt converted into shares, value		$ 3,145,777
Debt converted into shares | shares		20,350,573	20,350,573
Number of warrants cancelled | shares		560,461

XML

Development Grant (Details Narrative) - Canada-Israel Research and Development Foundation [Member]		12 Months Ended
	Jun. 07, 2013 USD ($)	Dec. 31, 2020 USD ($)	Jun. 07, 2013 CAD ($)
Grant repayable percentage	2.50%
Other income		$ 176,933
CAD [Member]
Funds for development activities	$ 225,000
Maximum [Member] | CAD [Member]
Funds for development activities			$ 300,000

XML

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2020 CAD ($)	Dec. 31, 2019 CAD ($)
Provision for income tax
Net operating loss, description	Carried forward over 20 years
CAD [Member]
Net operating loss			$ 8,603,671	$ 6,143,402

XML

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Deferred tax asset, beginning	$ 741,000	$ 704,000
Increase in valuation reserve	333,000	37,000
Deferred tax asset, ending	1,074,000	741,000
Valuation Allowance	(1,074,000)	(741,000)
Net Deferred tax assets

XML

Commitments and Contingencies (Details Narrative) - USD ($)			12 Months Ended
	Jan. 02, 2020	Jun. 24, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 29, 2019
General and administration expenses			$ 2,046,573	$ 411,019
Lease expenses			2,500
Office space and related expenses			$ 73,000	18,000
Benjamin Kaplan [Member]
Warrants exercise price			$ 0.01
General and administration expenses			$ 720,695
Accrued other payables			91,000	18,000
Collaboration Agreement [Member]
Royalty payment			10,000	5,000
Executive Consulting Agreement [Member]
General and administration expenses			1,040,694	$ 172,091
Executive Consulting Agreement [Member] | Benjamin Kaplan [Member]
Agreement term		24 months
Warrants exercise price					$ 0.01
Warrant expiry date					Apr. 16, 2022
Raised consideration value of significant transaction			$ 500,000
Owed share of common stock			15,624,694
Other payable and interest expenses			$ 1,874,963
Executive Consulting Agreement [Member] | Benjamin Kaplan [Member] | Minimum [Member]
Payment for contingent consideration			500,000
Payment of consideration for rendered services			$ 1,000,000
Consulting Agreement [Member]
Owed share of common stock			876,225
Consultant fee	$ 6,500
Other payable and consulting expenses			$ 109,159
Consulting Agreement [Member] | Common Stock [Member]
Consultant fee	4,000
Consulting Agreement [Member] | Cash [Member]
Consultant fee	$ 2,500
Medical Advisory Board Agreements [Member]
General and administration expenses			105,438
Accrued other payables			105,438
Medical Advisory Board Agreements [Member] | Common Stock [Member]
Payment of consideration for rendered services			155,000
Medical Advisory Board Agreements [Member] | Cash [Member]
Payment of consideration for rendered services			$ 10,000

XML

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)					12 Months Ended
	Sep. 15, 2020	Aug. 04, 2020	Aug. 02, 2020	Feb. 27, 2019	Dec. 31, 2020	Dec. 31, 2019
Stock issued					$ 26,250
Shares issued upon exercise of warrants					100,909
Number of warrants exercised					110,000
Debt principal amount				$ 2,845,414
Accrued interest				$ 300,362	$ 53,929	$ 51,075
Debt converted into shares				19,711,362
Stock based compensation expense		$ 50,000	$ 61,224
General and administrative expenses					$ 2,046,573	$ 411,019
Dividend rate					0.00%
Risk-free interest rate					0.44%
Expected volatility					162.24%
Number of stock issued for services		378,597	408,163
Number of warrants cancelled				2,250,000
Anti-dilution provisions for common shares				328,111
Intrinsic value of warrants outstanding					$ 2,926,612
Benjamin Kaplan [Member]
Shares issued upon exercise of warrants					3,358,498
Warrants issued during period, value					$ 720,695
General and administrative expenses					$ 720,695
Warrants exercise price					$ 0.01
Dividend rate					0.00%
Benjamin Kaplan [Member] | Minimum [Member]
Stock price					$ 0.37
Risk-free interest rate					0.13%
Expected volatility					648.00%
Benjamin Kaplan [Member] | Maximum [Member]
Stock price					$ 0.12
Risk-free interest rate					0.20%
Expected volatility					570.00%
Member of Management [Member]
Stock based compensation expense		$ 50,000
Number of stock issued for services		378,597
CAD [Member]
Debt principal amount				$ 3,740,431
Accrued interest				$ 394,693
Convertible Promissory Note [Member]
Shares issued for conversion of convertible securities					37,818,154
Shares issued upon exercise of warrants					2,544,870
Debt principal amount					$ 2,544,487
Debt converted into shares					37,818,154
Warrants exercise price					$ 0.01
Psychedelitech, Inc. [Member]
Number of shares purchased	1,050,000
Ownership percentage	10.00%
Cost of investment					$ 26,250
Bezalel Partners LLC [Member]
Number of stock issued for services				475,642
Number of stock issued for services, value				$ 237,821
KW Capital Partners Ltd [Member]
Number of stock issued for services				317,095
Number of stock issued for services, value				$ 158,547
Strategic Alliance Agreement [Member]
Stock issued, shares	1,050,000
Stock issued	$ 26,250
Asset Sale and Purchase Agreement [Member]
Stock issued, shares					353,622
Stock issued					$ 40,000
Finder's Fee Agreement [Member]
Stock issued, shares					1,250,000
Stock issued					$ 46,875
Compensation for services description					Total compensation for the consultant's efforts and services shall be a cash fee of 10% of the total principal amount of gross proceeds from any financing and 10% of the total shares of common stock purchased or convertible equivalent.
Stock based compensation expense					$ 63,500

XML

Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Shares outstanding, beginning balance		86,251
Shares outstanding, granted
Shares outstanding, exercised
Shares outstanding, canceled		(86,251)
Shares outstanding, ending balance
Weighted- average exercise price, beginning balance
Weighted- average exercise price, granted
Weighted- average exercise price, exercised
Weighted- average exercise price, canceled
Weighted- average exercise price, ending balance
Weighted average remaining contractual term (in years), beginning balance	0 years	5 years
Weighted average remaining contractual term (in years), granted	0 years	0 years
Weighted average remaining contractual term (in years), ending balance	0 years	0 years
Aggregate intrinsic value, beginning balance
Aggregate Intrinsic Value, ending balance

XML

Stockholders' Equity (Deficit) - Schedule of Warrants Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Underlying shares, beginning balance		561,461
Underlying shares, Granted	28,803,368
Underlying shares, Exercised	(110,000)
Underlying shares, Forfeited		561,461
Underlying shares, ending balance	28,693,368
Weighted average exercise price, beginning balance
Weighted average exercise price, granted	0.01
Weighted average exercise price, exercised	0.01
Weighted average exercise price, forfeited
Weighted average exercise price, ending balance	$ 0.01
Weighted average term (years), beginning balance	0 years	0 years
Weighted average term (years), granted	1 year 4 months 28 days	0 years
Weighted average term (years), ending balance	1 year 1 month 13 days	0 years

XML

Stockholders' Equity (Deficit) - Schedule of Stock Option Valuation Model Assumptions (Details)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Expected term, in years	2 years 9 months 29 days
Expected volatility	162.24%
Risk-free interest rate	0.44%
Dividend yield	0.00%

XML

Subsequent Events (Details Narrative) - USD ($)					12 Months Ended
	Jan. 31, 2021	Jan. 21, 2021	Jan. 19, 2021	Jan. 02, 2021	Dec. 31, 2020	Dec. 31, 2019
Value of shares issued upon conversion					$ 378,182
Value of shares purchase during the acquisition					40,000
Investments					$ 26,250
Common Stock [Member]
Number of shares issued upon conversion					37,818,154
Value of shares issued upon conversion					$ 378,182
Number of shares purchase during acquisition					353,622
Value of shares purchase during the acquisition					$ 40,000
Share issued					1,050,000
Asset Sale and Purchase Agreement [Member]
Share issued					353,622
Subsequent Event [Member]
Number of shares issued upon conversion				15,649,446
Value of shares issued upon conversion				$ 156,494
Cashless exercise of warrants				1,870,000
Subsequent Event [Member] | Promissory Notes [Member]
Proceeds from promissory note				$ 522,000
Debt description				The notes carry an additional original issue discount payable of $52,750 representing interest as no other interest accrues on the notes unless there is an event of default, at which time interest will accrue at 22.0%, The notes mature eighteen months after the dates of issuance. The holder of the notes can exercise conversion at any time the note remains outstanding at a price of $0.01 per share. Upon the closing of a financing event of the Company, the notes will automatically convert at the conversion price of $0.01 per share.
Debt original issue discount				$ 52,750
Debt instrument, interest rate				22.00%
Debt, conversion price per share				$ 0.01
Warrants exercise price				$ 0.01
Warrant term				2 years
Subsequent Event [Member] | Regulation A Offering [Member]
Investments	$ 1,159,000
Share issued	16,557,142
Subsequent Event [Member] | Common Stock [Member]
Share issued				1,746,084
Subsequent Event [Member] | Medical Advisory Board Agreement [Member] | Common Stock [Member]
Share issued				281,000
Subsequent Event [Member] | 20/20 Global [Member] | Common Stock [Member]
Number of shares purchase during acquisition			9,793,754
Equity method investment, ownership percentage			75.77%
Value of shares purchase during the acquisition			$ 350,000
Subsequent Event [Member] | 20/20 Global [Member] | Mycotopioa Therapies, Inc. [Member] | Stock Purchase Agreement [Member]
Purchase value of shares			$ 350,000
Subsequent Event [Member] | CureDash, Inc [Member] | Asset Sale and Purchase Agreement [Member]
Purchase price asset payable		$ 100,000
Shares issued related to asset purchase		353,622
Cash paid related to asset purchase		$ 60,000